Garadacimab (CSL312) is a first-in-class, fully humanIgG4monoclonal antibody targetingactivated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research^[1].

Garadacimab (CSL312) displays high affinity to activated βFXIIa with a K_Dof 140 pM and shows potency in an activated partial thromboplastin time (aPTT) assay with human plasma. Garadacimab shows high selectivity over a panel of relevant human serine proteases (FVIIa, FIXa, FXa, FXIa, kallikrein, tissue plasminogen activator, activated protein C, and urokinase plasminogen activator)^[2].

In male and female cynomolgus monkeys, Garadacimab (0.5, 1, and 3 mg/kg i.v. and 6 and 20 mg/kg s.c. over 8 weeks) plasma concentrations increased in a dose-dependent manner^[1].
Garadacimab has an inhibitory effect on FXII-mediated kallikrein activity. Furthermore, Garadacimab causes a clear dose-dependent prolongation of activated partial thromboplastin time (aPTT) with no associated effect on the prothrombin time^[1].

2162134-62-3

加达西单抗

Please store the product under the recommended conditions in the Certificate of Analysis.